How PPMI Enabled the First Interventional Platform Trial to Test Therapies in Participants With Early‐Stage Neuronal Alpha‐Synuclein Disease

Overview of attention for article published in Annals of Neurology, May 2026

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

news: 1 news outlet
twitter: 2 X users

bluesky: 3 Bluesky users

Readers on

mendeley: 3 Mendeley

So far, Altmetric has seen 3 Bluesky posts from 3 Bluesky users, with an upper bound of 154 followers.

How PPMI Enabled the First Interventional Platform Trial to Test Therapies in Participants With Early‐Stage Neuronal Alpha‐Synuclein Disease #NeuroDegeneration 🧪🧠 https://onlinelibrary.wiley.com/doi/10.1002/ana.78250?af=R

An invited editorial explores how the Michael J Fox Foundation's PPMI programme is enabling the first interventional platform trial ("Path to Prevention" or P2P) to test therapies in individuals with Early-Stage Neuronal Alpha-Synuclein Disease online…

RRIDs were included in this in Annals of Neurology paper. We value the author's support of reproducibility. #STMpublishing #OpenScience #OpenResearch

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.